(PBIO) Pressure BioSciences Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.
Pressure Biosciences laid out its goals on Wednesday. May 18. 2016 which includes implementation of financial self-sufficiency and future growth and profitability as well as preparation for a targeted up-list to NASDAQ or the NYSEMKT.
Cancer Moonshot Should Benefit Pharma Companies, Investors
Sept, 6, 2016
Pressure BioSciences, Inc. Reports Second Quarter 2016 Financial Results and Provides Business Update
Aug. 16, 2016
StockWatchIndex Research Report
July 21, 2016
Pressure BioSciences Unveils Barocycler 2320EXT at Major Scientific Meeting; Next Generation PCT-based Instrument Expected to be Centerpiece of the Recently Announced Co-Marketing Agreement with Global Life Sciences Analytical Technologies Leader SCIEX
July 13, 2016
PBIO: Update on First Quarter 2016 Financials
June 8, 2016
WallStreet Research(TM) Announces Availability of Updated Corporate Profile Coverage On Pressure BioSciences, Inc. (OTCQB: PBIO)
May 31, 2016
SeeThruEquity Issues Update on Pressure BioSciences (OTCQB: PBIO), Raises Price Target to $1.75
May 26, 2016
SECFilings.com Reports on Pressure BioSciences' Q1 2016 Financial Results
May 25, 2016
Pressure BioSciences' (PBIO) CEO on Q1 2016 Results - Earnings Call Transcript
May 18, 2016
Pressure BioSciences, Inc. Reports First Quarter 2016 Financial Results and Provides Business Update
May 18, 2016